eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

2/2009
vol. 1
 
Share:
Share:
abstract:

Original article
Trans-hepatic technique and intraluminal Pulsed Dose Rate (PDR-BT) brachytherapy in treatment of locally advanced bile duct and pancreas cancer

Janusz Skowronek
,
Aleksander Sowier
,
Paweł Skrzywanek

J Contemp Brachyther 2009; 1, 2: 97-104
Online publish date: 2009/07/17
View full text Get citation
 
Purpose: To assess the feasibility of intraluminal palliative Pulsed Dose Rate (PDR-BT) brachytherapy in the treatment of locally advanced bile duct and pancreas cancer.
Material and methods: Forty-eight patients with advanced bile duct or pancreas cancer, disqualified from surgery or radical external beam radiation therapy (EBRT), were treated with trans-hepatic technique and intraluminal PDR-BT: 29 patients with bile duct cancer and 19 – pancreas cancer. Forty-four patients were treated exclusively with PDR-BT, 4 with PDR–BT and concomitant chemotherapy or surgery. Percutaneous trans-hepatic technique was used to implant the catheter into bile ducts. Most of patients (38/48, 79%) received 25 pulses of 0.8 Gy hourly with the total dose of 20 Gy. In 8 cases PDR was repeated after one week. Target volume encompassed tumor visualized at cholangiography with one or two cm margin measured proximally and distally. Dose was prescribed at 10-15 mm from the source axis.
Results: In all cases trans-hepatic technique allowed insertion of BT catheter into bile duct and safe application of PDR-BT. In 19 out of 29 (65.5%) of bile duct cancer cases and in 10 out of 19 (52.6%) of pancreas cancer patients clinical improvement (decrease of jaundice) was noted in first control after 4 weeks. Median overall survival time (OS) for bile ducts cancer patients was 11.2 months and for pancreas cancer patients – 5.2 months.
Conclusions: 1. It has been established, that the use of PDR-BT was feasible and had a low early complication rate. A new percutaneous trans-hepatic technique allowed the treatment (insertion of catheter, PDR brachytherapy) to be performed in one day. 2. In most cases a satisfied palliative effect was achieved, however it was more apparent in bile duct cancer patients then in pancreas cancer patients.
keywords:

bile duct cancer, pancreas cancer, PDR brachytherapy

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.